Animal-Assisted Therapy in the Residential Treatment of Schizophrenia and Addictions

Diagnosis, Dual (Psychiatry) Clinical Trial

Official title:

Animal-Assisted Therapy in the Residential Treatment of Schizophrenia and Addictions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05103865
• Other study ID #: AAT S&A
• Status: Completed
• Phase: N/A
• Start date: November 3, 2015
• Est. completion date: September 10, 2019

Study information

• Verified date: October 2021
• Source: Cardenal Herrera University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Animal-assisted therapy (AAT) is a complementary intervention of therapy that has shown positive results in the treatment of various pathologies. This study assesses the viability of the implementation and the efectiveness of an AAT program in patients diagnosed with substance abuse disorder and associated mental disorders (dual pathology).

Description:

Animal assisted therapy (AAT) is a complementary intervention to therapy that presents positive results in the treatment of different pathologies. The study assesses the implementation and effectiveness of a TAA program in patients diagnosed with substance use disorder and schizophrenia spectrum disorder.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Est. completion date: September 10, 2019
• Est. primary completion date: May 20, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Meeting DSM-5 criteria for substance abuse disorder and the presence of schizophrenia

• Voluntary participant in the study and having signed the informed consent

Exclusion Criteria:

• Patients whose functioning could be altered by factors not specifically related to addictive pathology or mental disorder (severe cognitive impairment, intellectual deficiency or language barrier)

• Animal-specific phobia

Related Conditions & MeSH terms

• Diagnosis, Dual (Psychiatry)
• Schizophrenia

Intervention

Behavioral:
• Animal-assisted therapy (AAT)

Other:
• usual treatment

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Miguel Monfort Montolio

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Life Skills Profile questionnaire (LSP)	This questionnaire evaluates aspects of functioning that affect daily activities and the adaptation of people with mental illnesses in the community. It contains 39 items that are grouped into self-care, social-interpersonal behaviour, communication-social contact, non-personal social behaviour and autonomous life	Change from Life Skills at 3-6-9 months (12 minutes)
Primary	Barrat impulsiveness scale (BIS-11)	This instrument is composed of 30 items distributed into three sub-scales: nonplanning, motor and attentional. The total impulsiveness score was also obtained.	Change from impulsiveness at 3-6-9 months (12 minutes)
Primary	Calgary Depresión Scale for Schizophrenia (CDSS)	El cuestionario es un intrumento estructurado, adminisitrado por un clínico de forma heteroaplicada para población adulta, con un tiempo aproximado de administración de entre 10 y 30 minutos, y aborada el área terapéutica relativa a la sintomatología de los trastornos depresivos.	Change from Depresión at 3-6-9 months (12 minutes)
Primary	Rosenberg Self-Esteem Scale	The questionnaire consists of 10 statements of the feelings that the person has about himself. Five of the statements are addressed positively (items 1, 2, 4, 6 and 7) and 5 negatively (items 3, 5, 8, 9 and 10).	Change from self.-esteem at 3-6-9 months (12 minutes)
Primary	Positive and negative symptom scale (PANSS)	It is a semi-structured and hetero-applied questionnaire for the adult population. The application time is between 30-60 minutes and evaluates the positive and negative symptoms of schizophrenia and other psychotic disorders.	Change from Positive and negative symptom at 3-6-9 months (12 minutes)